Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Teriparatide

Nature Reviews Drug Discovery volume 2, pages 257–258 (2003)Cite this article

Abstract

Teriparatide (Forteo; Eli Lilly), a recombinant form of the 34 amino-terminal amino acids of human parathyroid hormone, was approved by the US FDA in November 2002 for the treatment of osteoporosis. As the first agent to stimulate bone formation, rather than just reduce bone loss, what impact is it likely to have on the osteoporosis drug market?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Effects of parathyroid hormone.
Figure 2: Osteoporosis drug market.

References

  1. Goltzman, D. Discoveries, drugs and skeletal disorders. Nature Rev. Drug Discov. 1, 784–796 (2002).

    Article  CAS  Google Scholar 

  2. Cummings, S. R. & Melton, L. J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359, 1761–1767 (2002).

    Article  Google Scholar 

  3. Rubin, M. R. & Bilezikian, J. P. New anabolic therapies in osteoporosis. Curr. Opin. Rheumatol. 14, 433–440 (2002).

    Article  CAS  Google Scholar 

  4. FDA Drug Approvals List [online] (cited 28 February 2003) < http:2002/21318_forteo_lbl.pdf > (2002).

  5. Neer, R. et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001).

    Article  CAS  Google Scholar 

  6. Orwoll, E. S. et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18, 9–17 (2003).

    Article  CAS  Google Scholar 

  7. Lilly Forteo risk management program limits launch to 8,000 doctors. The Pink Sheet 64, 7–8 (2002).

Download references

Author information

Authors and Affiliations

  1. Decision Resources Inc., 260 Charles Street, Waltham, 020453, Massachusetts, USA

    Carilee Berg & Kat Neumeyer

  2. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Carilee Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kat Neumeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carilee Berg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berg, C., Neumeyer, K. & Kirkpatrick, P. Teriparatide. Nat Rev Drug Discov 2, 257–258 (2003). https://doi.org/10.1038/nrd1068

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1068

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing